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Abstract
The individual activity of antibiotics such as ampicillin, tetracycline, erythromycin and gentamicin in combination with
compounds known to modify bacterial resistance to given antibiotics was studied using the checkerboard method. The
combination of promethazine with either ampicillin, tetracycline or erythromycin or the combination of methylene blue and
erythromycin produced significant synergistic activity against Escherichia coli. Verapamil, however, in combination with ampicillin
reduced the activity of ampicillin against E. coli. Combinations of clomipramine with either tetracycline or erythromycin,
promethazine and erythromycin or verapamil and ampicillin were synergistic against Staphylococcus epidermidis that was resistant
to these antibiotics. The only synergy against Pseudomonas aeruginosa was shown by the combination of methylene blue and
gentamicin. © 2000 Elsevier Science B.V. and International Society of Chemotherapy. All rights reserved.
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1. Introduction
Tricyclic neuroleptics and antidepressants have direct
activity against bacteria [1–5] and mycobacteria [6],
enhance the activity of specific antibiotic [7–10], reverse
the natural resistance of specific bacteria to given an-
tibiotics [8,9,11], promote the elimination of plasmids
from Escherichia coli [4,12], and inhibit transport func-
tions of the plasma membrane to given antibiotics
[11,13]. Inhibition of plasma membrane based efflux
pumps have been observed with a variety of phenothi-
azines and their derivatives [5].
The enhancement of antibiotic activity or the reversal
of antibiotic resistance by non-conventional antibiotics
affords the classification of these compounds as
modifiers of antibiotic activity [11,13–15]. Verapamil
(VP) is a well known modifier of antibiotic resistance.
This compound, as well as the phenothiazines-
methylene blue and promethazine (PZ), and the struc-
turally related clomipramine were tested for their
potential separate interaction with four representative
antibiotics-ampicillin, erythromycin, gentamicin and te-
tracycline against E. coli, Staphylococcus epidermidis
and Pseudomonas aeruginosa using the checkerboard
method [16].
2. Materials and methods
2.1. Antibiotics
Ampicillin (AMP) (Beecham Research Laboratories,
UK), tetracycline (TET) and gentamicin (GENT) (Chi-
noin, Budapest, Hungary), erythromycin (ERY)
(Richter Gedeon Rt, Budapest, Hungary).
* Corresponding author. Tel.: 36-62-455115; fax: 36-62-
455113.
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2.2. Modifiers of antibiotic acti6ity
Promethazine (PZ) (Pipolphen EGIS, Budapest,
Hungary), methylene blue (MB) (Reanal, Budapest,
Hungary), clomipramine (CP, Anaphranil) (Ciba,
Beigy, Basel, Switzerland), verapamil (VP) (Chinoin,
Budapest, Hungary).
2.3. Checkerboard method
The checkerboard method [17] is the technique used
most frequently to assess antimicrobial combinations in
vitro. Dilutions of the antimicrobials and resistance
modifiers were made in minimal tryptone yeast (MTY)
broth for the evaluation of interactions and antibacte-
rial effects. The results of the combined effect of antibi-
otics and interpreted modifiers were evaluated for
synergism, additive, indifference or antagonism. Three
bacterial strains were tested by the microdilution check-
erboard technique. Dilutions from the logarithmic-
growth phase of bacterial cultures were prepared and
distributed into microtiter trays containing varying con-
centrations of the different drugs. The final inoculum
size per microtiter well was approximately 105 colony
forming unit (CFU):ml. The inoculated trays were in-
cubated at 37°C for a period of 24 h, and then evalu-
ated for bacterial growth. In order to evaluate the
activity of combinations of drugs, fractional inhibitory
concentration (FIC) indices were calculated as FICA
FICB, where FICA and FICB represent the minimum
concentrations that inhibited the bacterial growth for
drugs A and B, respectively.
FICA
MICA combination
MICA alone
FICB
MICB combination
MICB alone
A mean FIC index was calculated based on the
following equation: FICindexFICAFICB and the in-
terpretation made as follows: synergistic(B0.5), addi-
tive (0.5–1.0), indifferent (\1), or antagonistic
(\4.0).
2.4. Bacterial strains
Escherichia coli K12 LE 140 tsx, str, D lac, su-, lr,
mal-, Pseudomonas aeruginosa and Staphylococcus epi-
dermidis were clinical isolates. The bacterial strains
were cultured in MTY broth [18].
3. Results
The strain of E. coli used in this study was suscepti-
ble to ampicillin, tetracycline, erythromycin and gen-
tamicin with MIC’s of 4.0, 1.0, 8.0 and 1.0 mg:l
respectively. This strain was resistant to promethazine
(MIC128 mg:l), methylene blue (400 mg:l),
clomipramine (64 mg:l) and verapamil (1250 mg:l).
Table 1 shows the results of the combinations of
antibiotics and the resistance modifiers, at or below
their MIC. Promethazine, methylene blue or
clomipramine by themselves have limited inhibitory
activity against E. coli. They however, enhance the
activity of ampicillin at concentrations that was not
inhibitory. Synergism was not observed with combina-
tions of ampicillin and verapamil. At concentrations
equal to each MIC, the result was antagonism. The
Table 1
MIC of antibiotics and the effect of combinations with resistance
modifiers against E. coli
Antibioticsresistance Type of interac-MIC (mg l1)
modifiers tion
128Promethazine (PZ)
400Methylene blue (MB)
64Clomipramine (CP)
\1250Verapamil (VP)
Ampicillin (AMP) 4
PZ AMP (1)PZ Synergy
(16)
AMP (1)MB SynergyMB
(25)
CP SynergyAMP (1)CP
(16)
VP AMP (1)VP Antagonism
(\1250)
1Tetracycline (TET)
PZ TET (0.25)PZ Synergy
(32)
AdditiveMB TET (0.50)MB
(32)
TET (0.25)CP AdditiveCP
(32)
TET (1)VP (\VP Indifferent
1250)
8Erythromycin (ERY)
ERY (1)PZPZ Synergy
(32)
MB ERY (2)MB Snergy
(50)
ERY (4)CP AdditiveCP
(32)
VP ERY (4)VP (\ Additive
1250)
Gentamicin (GENT) 1
AdditivePZ GENT (0.5)PZ
(64)
MB GENT (0.5) Additive
MB (25)
GENT (0.5)CP AdditiveCP
(32)
GENT (1)VP IndifferentVP
(\1250)
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Table 2
MIC of antibiotics and the effect of combinations with resistance
modifiers against S. epidermidis
MIC (mg l1)Antibioticsresistance Type of interac-
tionmodifiers
64Promethazine (PZ)
400Methylene blue (MB)
64Clomipramine (CP)
\1250Verapamil (VP)
256Ampicillin (AMP)
AMP (128)PZ AdditivePZ
(32)
AMP (128)MBMB Additive
(25)
AMP (64)CPCP Additive
(32)
AMP (256)VPVP Indifferent
(\1250)
Tetracycline (TET) 32
TET (4)PZPZ Synergy
(16)
TET (16)MBMB Additive
(50)
SynergyCP TET (8)CP (8)
VP IndifferentTET (32)VP
(\1250)
Erythromycin (ERY) 64
ERY (16)PZPZ Synergy
(16)
ERY (16)MBMB Additive
(50)
CP ERY (2)CP (4) Synergy
VP IndifferentERY (64)VP
(\1250)
Gentamicin (GENT) 0.5
GENT (0.25) AdditivePZ
PZ (16)
GENT (0.25)MB Additive
MB (25)
GENT (0.25)CP Additive
CP (32)
GENT (0.5)VPVP Indifferent
(\1250)
4. Discussion
The direct antibacterial activity of phenothiazines
against susceptible bacteria has been studied over many
years [12,19]. The use of these compounds for the
management of bacterial infections has not been at-
tempted because the concentrations that inhibit bacte-
rial growth in vitro [15] are not clinically achievable.
Some of these compounds are also known to produce
serious side effects. Nevertheless, administration of clin-
ical doses of the phenothiazine, promethazine as an
adjuvant to conventional antibiotic therapy for difficult
paediatric bacterial infections has yielded significant
Table 3
MIC of antibiotics and the effect of combinations with resistance
modifiers against Pseudomonas aeruginosa
Antibioticsresistance MIC (mg l1) Type of interaction
modifiers
Promethazine (PZ) 256
400Methylene blue (MB)
256Clomipramine (CP)
1250Verapamil (VP)
Ampicillin (AMP) 256
PZ AdditiveAMP (128)PZ
(128)
AMP (128) AdditiveMB
MB (50)
CP AMP (128)CP Additive
(128)
AMP (256)VPVP Indifferent
(\1250)
16Tetracycline (TET)
TET (8)PZPZ Additive
(64)
TET (8)MB AdditiveMB
(50)
TET (8)CPCP Additive
(128)
TET(4)VP Indifferent
VP(\1250)
Erythromycin (ERY)
ERY (32)PZPZ Additive
(128)
MB AdditiveERY (32)MB
(50)
CP ERY (32)CP Additive
(128)
VP ERY (64)VP Indifferent
(\1250)
Gentamicin (GENT)
AdditiveGENT (0.5)PZ
PZ (64)
SynergyGENT (0.25)MB
MB (25)
AdditiveGENT (0.25)CP
CP (128)
VP IndifferentGENT (1)VP
(\1250)
combinations of resistance modifiers and tetracycline,
erythromycin, gentamicin gave varied responses. Of the
four resistance modifiers employed, synergism was ob-
served with promethazine in combination with tetracy-
cline and erythromycin, and with the combination of
methylene blue and erythromycin.
The synergism shown by promethazine against S.
epidermidis was much less than that against
E. coli (Table 2). Promethazine acted synergistically
with tetracycline and erythromycin. Clomipramine and
erythromycin was also synergistic against S. epider-
midis. Against Pseudomonas aeruginosa, the only syn-
ergy was seen with methylene blue and gentamicin
(Table 3).
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success when compared to the use of the antibiotic
alone [8]. This enhancement of antibiotic activity
against selected species of bacteria has been reproduced
in vitro with various phenothiazines in combination
with gentamicin [8] and other drugs [19].
The mechanism by which phenothiazines, its deriva-
tives, and structurally similar compounds, in enhancing
the activity of conventional antibiotics, has been postu-
lated to involve functional alterations of the plasma
membrane of bacteria, to the extent that transport
mechanisms are affected [5]. The direct action of the
phenothiazines on the permeability of the membrane
itself has also been considered [20].
E. coli, P. aeruginosa and S. epidermidis are resistant
to phenothiazines and its compounds since the concen-
trations that inhibit growth exceed 60 mg:l as shown in
this and other studies [4,12]. These organisms are well
suited for studies of potential enhancement of antibiotic
activity by such compounds. The results obtained in
this study did not identify any consistent activity of any
resistance modifier in any combination with a given
antibiotic when challenged against different species of
bacteria. The activity of these compounds, at the level
of the plasma membrane, is modified by the nature of
the cell wall, and thus is species specific. The activity
when present, is the result of interaction of the antibi-
otic and the compound external to the membrane itself.
The latter possibility has been proposed by other work-
ers [2]. Synergistic activities demonstrable for a given
combination of antibiotic and modifier of antibiotic
activity for a species of bacteria may indeed prove
clinically useful if such activity is present consistently
for strains of that species.
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